Pfizer pushes further into generics, with 39 products from India's Aurobindo
Hot on the heels of US President Barack Obama's announcement that he will back the generic drug sector in the USA (see page 14), global pharmaceutical behemoth Pfizer said that it has entered into a series of agreements with India's Aurobindo Pharma, to commercialize medicines that are no longer patent protected, and have lost market exclusivity in the USA and Europe, further progressing the US company's Established Products Business Unit strategy which was set up last year. Financial terms of the deal were not disclosed
This Pfizer Unit was launched in 2008 as part of the company's initiative to create smaller, more accountable businesses aligned with customer needs. Currently, it has annual sales of $10.0 billion globally.
Targeting incremental sales
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze